22 Results for "

locomotor disorders

" in MedChemExpress (MCE) Product Catalog:
Products (22)

22 Results for "locomotor disorders" in MCE Product Catalog:

8
8 Publications Verification
Cat. No.: HY-14197A
CAS No.: 17780-75-5
Purity:  99.92%
Synonyms: M&B 9302 hydrochloride
Clorgyline hydrochloride (M&B 9302 hydrochloride) is a selective, irreversible monoamine oxidase A (MAO-A) inhibitor that can cross the blood-brain barrier and exhibits activity against the 5-HT Receptor at very high doses. Clorgyline hydrochloride regulates monoamine neurotransmitter levels, the release of dopamine and acetylcholine, the uptake and effects of Tyramine (HY-W007606), noradrenergic function, circadian locomotor activity rhythms, feeding behavior, and body weight. Clorgyline hydrochloride induces tumor-suppressive transcriptional programs, secretory differentiation, androgen signaling regulation, Bcl-2 expression, and radioprotective effects in non-malignant cells. Clorgyline hydrochloride is used in the research of high-grade prostate cancer, Huntington's disease, major affective disorder, radiation-induced normal tissue toxicity, and obesity .
loading...
    loading...
8
8 Publications Verification
Cat. No.: HY-14197
CAS No.: 17780-72-2
Purity:  99.76%
Synonyms: M&B 9302
Clorgyline (M&B 9302) is a selective, irreversible monoamine oxidase A (MAO-A) inhibitor that can cross the blood-brain barrier and exhibits activity against the 5-HT Receptor at very high doses. Clorgyline regulates monoamine neurotransmitter levels, the release of dopamine and acetylcholine, the uptake and effects of Tyramine (HY-W007606), noradrenergic function, circadian locomotor activity rhythms, feeding behavior, and body weight. Clorgyline induces tumor-suppressive transcriptional programs, secretory differentiation, androgen signaling regulation, Bcl-2 expression, and radioprotective effects in non-malignant cells. Clorgyline is used in the research of high-grade prostate cancer, Huntington's disease, major affective disorder, radiation-induced normal tissue toxicity, and obesity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-117771
CAS No.: 1848233-58-8
Purity:  99.30%
Target:  

DAGL

DO34 is a selective DAGL inhibitor, with an IC50 of 6 nM for DAGLα conversion of SAG to 2-AG. DO34 blocks de novo 2-AG synthesis, and suppresses tonic CB1 receptor activation. DO34 blocks depolarization-induced suppression of excitation and inhibition in the cerebellum and hippocampus. DO34 regulates feeding behavior and locomotor activity in mice. DO34 abolishes AM251-mediated enhancement of parallel fiber-evoked excitatory postsynaptic currents in cerebellar slices from MAGL global knockout mice. DO34 can be used for the research of energy balance disorder and neuroinflammation .
loading...
    loading...
Cat. No.: HY-W013150
CAS No.: 82626-01-5
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions .
loading...
    loading...
Cat. No.: HY-175188
CAS No.: 2404652-82-8
Synonyms: BPN-0027490
Target:  

Myosin

Research Areas:  

Neurological Disease

MT-110 (BPN-0027490) is a non-muscle myosin NMIIB-selective inhibitor with high brain penetration and favorable safety profile. MT-110 specifically disrupts NMIIB-dependent actin dynamics in dendritic spines, while it exerts no significant adverse effects on cardiac myosin II and cardiac functions (such as cardiac output and heart rate) at tested concentrations. A single administration of MT-110 produces long-lasting (sustained for several weeks) blockade of methamphetamine motivation associated with environmental cues. MT-110 exhibits extremely high specificity, with no interference with cocaine motivation, hippocampus-dependent memory, fear memory, or locomotor and anxiety-like behaviors. MT-110 serves as a valuable tool compound for investigating the mechanisms of methamphetamine use disorder .
loading...
    loading...
Cat. No.: HY-171844
CAS No.: 1086377-48-1
Target:  

iGluR

CX1739 is an orally active, blood-brain barrier permeable, low-efficacy AMPA-glutamate receptor (AMPAR) potentiator. CX1739 enhances excitatory neurotransmission by potentiating glutamate-induced excitatory currents and promoting in vivo long-term potentiation. CX1739 eliminates amphetamine-induced locomotor activity, reverses opioid-, pentobarbital- and ethanol-induced respiratory depression, and exerts pro-cognitive effects in animals. CX1739 impairs motor function recovery and increases the risk of post-injury complications. CX1739 can be used in research related to attention-deficit/hyperactivity disorder, dementia, respiratory depression and spinal cord injury .
loading...
    loading...
Cat. No.: HY-172550
CAS No.: 3095336-10-7
Target:  

HCN Channel

Research Areas:  

Neurological Disease

MS7710 is a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel inhibitor with blood-brain barrier permeability and an excellent brain/plasma concentration ratio. MS7710 inhibits HCN channel-mediated Ih current, and reduces the firing frequency and burst activity of dopaminergic neurons in the ventral tegmental area. MS7710 ameliorates chronic social defeat stress-induced deficits in social interaction and impairments in reward-related cognitive flexibility in mice. MS7710 exerts only limited effects on ventral tegmental area dopaminergic neuron activity, social interaction, exploratory behavior, locomotor activity or sucrose preference in control mice. MS7710 is applicable to the research of major depressive disorder .
loading...
    loading...
Cat. No.: HY-117771A
CAS No.: 2098969-71-0
Purity:  98.42%
Target:  

DAGL

DO34 analog is a structural analog of DO34 (HY-117771). DO34 is a selective DAGL inhibitor, with an IC50 of 6 nM for DAGLα conversion of SAG to 2-AG. DO34 blocks de novo 2-AG synthesis, and suppresses tonic CB1 receptor activation. DO34 blocks depolarization-induced suppression of excitation and inhibition in the cerebellum and hippocampus. DO34 regulates feeding behavior and locomotor activity in mice. DO34 abolishes AM251-mediated enhancement of parallel fiber-evoked excitatory postsynaptic currents in cerebellar slices from MAGL global knockout mice. DO34 can be used for the research of energy balance disorder and neuroinflammation .
loading...
    loading...
Cat. No.: HY-P3568
CAS No.: 113800-65-0
Synonyms: Grybi-AKH
Target:  

Inhibitory Antibodies

Research Areas:  

Metabolic Disease

Adipokinetic hormone Gryllus bimaculatus (Grybi-AKH) is an adipokinetic hormone that regulates energy homeostasis in insects by mobilizing lipid and carbohydrate from the fat body. Adipokinetic hormone Gryllus bimaculatus stimulates the locomotor activity of the two-spotted cricket. Adipokinetic hormone Gryllus bimaculatus can also be used in studies to regulate body weight, induce weight loss and alleviate glycogen storage disorders in humans .
loading...
    loading...
Cat. No.: HY-P10405A
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

TAT-D1 peptide acetate is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide acetate disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide acetate produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide acetate can be used in the research of psychostimulant addiction, depression and anxiety disorders .
loading...
    loading...
Cat. No.: HY-P10405
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

TAT-D1 peptide is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide can be used in the research of psychostimulant addiction, depression and anxiety disorders .
loading...
    loading...
Cat. No.: HY-W013150R
CAS No.: 82626-01-5
Research Areas:  

Neurological Disease

Alpidem (Standard) is the analytical standard of Alpidem (HY-W013150). This product is intended for research and analytical applications. Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions.
loading...
    loading...
Cat. No.: HY-W013150S
CAS No.: 1189962-23-9
Alpidem-d14 is the deuterium labeled Alpidem (HY-W013150) . Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions.
loading...
    loading...
Cat. No.: HY-14197AR
CAS No.: 17780-75-5
Synonyms: M&B 9302 hydrochloride (Standard)
Clorgyline hydrochloride (Standard) (M&B 9302 hydrochloride (Standard)) is the analytical standard of Clorgyline hydrochloride (HY-14197A). This product is intended for research and analytical applications. Clorgyline hydrochloride (M&B 9302 hydrochloride) is a selective, irreversible monoamine oxidase A (MAO-A) inhibitor that can cross the blood-brain barrier and exhibits activity against the 5-HT Receptor at very high doses. Clorgyline hydrochloride regulates monoamine neurotransmitter levels, the release of dopamine and acetylcholine, the uptake and effects of Tyramine (HY-W007606), noradrenergic function, circadian locomotor activity rhythms, feeding behavior, and body weight. Clorgyline hydrochloride induces tumor-suppressive transcriptional programs, secretory differentiation, androgen signaling regulation, Bcl-2 expression, and radioprotective effects in non-malignant cells. Clorgyline hydrochloride is used in the research of high-grade prostate cancer, Huntington's disease, major affective disorder, radiation-induced normal tissue toxicity, and obesity .
loading...
    loading...
Cat. No.: HY-137231
CAS No.: 100609-40-3
Target:  

nAChR

Research Areas:  

Neurological Disease

UFR2709 hydrochloride is a blood-brain barrier-permeable, non-selective competitive antagonist of neuronal nicotinic acetylcholine receptors (nAChR). UFR2709 hydrochloride exerts anxiolytic effects in adult zebrafish, reduces alcohol-seeking behavior, ethanol consumption and ethanol preference in rats, increases water intake in rats, and does not alter locomotor/grooming activity or body weight in rats. UFR2709 hydrochloride can be used in research related to anxiety disorders, nicotine addiction, alcoholism and alcohol dependence .
loading...
    loading...
Cat. No.: HY-179568
CAS No.: 926493-93-8
Target:  

Monoamine Transporter

Research Areas:  

Neurological Disease

F3288-0031 is a brain-penetrant norepinephrine transporter (NET) allosteric inhibitor with inhibitory rates of 73.5% at 20 μM. F3288-0031 binds within the inner vestibule of NET, stabilizing the inward-open state and has a preferential NET/SERT inhibition with pIC50 = 5.9. F3288-0031 shows no detectable off-target functional activity in vitro. F3288-0031 demonstrates robust antidepressant-like efficacy in vivo without confounding locomotor effects, F3288-0031 can be used for depressive disorder and related neuropsychiatric conditions .
loading...
    loading...
Cat. No.: HY-184590
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

AB12-82 is a selective dopamine receptor agonist with a Ki value of 1.88 nM for human D3R. AB12-82 achieves subtype-selective D3R activation by enhancing interactions with the D3R H291·32 residue. AB12-82 can be used in the research of nervous system-related diseases .
loading...
    loading...
Cat. No.: HY-128319
CAS No.: 497926-94-0
Target:  

Dopamine Transporter

Research Areas:  

Neurological Disease

KM822 is a dopamine transporter (DAT) inhibitor with an IC50 of 2.2 μM against hDAT and an IC50 of 10.4 μM against C. elegans DAT-1. KM822 binds to the allosteric A2 site in the extracellular vestibule of outward-facing DAT, reduces the affinity of psychostimulants and phenethylamine psychostimulants for DAT, and inhibits dopamine transport function. KM822 attenuates the behaviors induced by psychostimulants and phenethylamine psychostimulants in planarians and C. elegans, does not induce locomotor effects on its own, and exhibits specificity for DAT. KM822 can serve as a molecular probe for investigating the allosteric regulation of DAT function. KM822 is applicable to studies related to psychostimulant use disorders .
loading...
    loading...
Cat. No.: HY-15080
CAS No.: 143691-37-6
Synonyms: LY 293606
Target:  

iGluR

GYKI 53405 (LY 293606) is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABAA, GABAB or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia .
loading...
    loading...
Cat. No.: HY-184591
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

AB13-73A is a highly selective partial agonist of dopamine D3R, with a Ki of 0.803 nM and a pEC50 of 11.88 (1.32 pM). AB13-73A serves as a pharmacological tool to dissect the (patho) physiological mechanisms of D3R and support the development of improved neurotherapeutic agents .
loading...
    loading...